Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.

Literature DB >> 18465662

ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.

Abstract

ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18465662

Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472

Keyword Cloud
Cited

14 in total

Review 1. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors: Pauline L Martin; Peter J Bugelski
Journal: Br J Pharmacol Date: 2012-06 Impact factor: 8.739

2. A novel class of anti-IL-12p40 antibodies: potent neutralization via inhibition of IL-12-IL-12Rβ2 and IL-23-IL-23R.

Authors: Adam W Clarke; Lynn Poulton; Hoi Yi Wai; Stuart A Walker; Shanti David Victor; Teresa Domagala; Dragana Mraovic; Danyal Butt; Nina Shewmaker; Philip Jennings; Anthony G Doyle
Journal: MAbs Date: 2010-09-01 Impact factor: 5.857

Review 3. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Authors: Michele W L Teng; Edward P Bowman; Joshua J McElwee; Mark J Smyth; Jean-Laurent Casanova; Andrea M Cooper; Daniel J Cua
Journal: Nat Med Date: 2015-06-29 Impact factor: 53.440

Review 4. Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors: Christopher G Mayne; Calvin B Williams
Journal: Inflamm Bowel Dis Date: 2013-07 Impact factor: 5.325

Review 5. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.

Authors: Wolfgang Weger
Journal: Br J Pharmacol Date: 2010-06 Impact factor: 8.739

Review 6. The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease.

Authors: Stewart Leung; Xuebin Liu; Lei Fang; Xi Chen; Taylor Guo; Jingwu Zhang
Journal: Cell Mol Immunol Date: 2010-04-12 Impact factor: 11.530

ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.

Review 1. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

2. A novel class of anti-IL-12p40 antibodies: potent neutralization via inhibition of IL-12-IL-12Rβ2 and IL-23-IL-23R.

Review 3. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Review 4. Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Review 5. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.

Review 6. The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease.

7. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis.

Review 8. Interleukin-23: as a drug target for autoimmune inflammatory diseases.

Review 9. The role of cytokines in Guillain-Barré syndrome.

Review 10. Ustekinumab: a new option in psoriasis therapy.